Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.

PURPOSE The aim of this study is to analyze, during the prostate-specific antigen (PSA) era, the long-term outcome of patients treated with conformal high-dose-rate (HDR) brachytherapy boost to the prostate with or without androgen deprivation therapy (ADT) when patients are stratified by risk factors for failure. METHODS AND MATERIALS Between 1986 and 2000, 611 patients were treated for clinically localized prostate cancer in three prospective trials of external beam radiation therapy (EBRT) and dose-escalating HDR brachytherapy (BT) boost. There were 104 patients treated at Seattle, 198 at Kiel University, and 309 at William Beaumont Hospital. Of the 611 patients, 177 received a short course of neoadjuvant/concurrent ADT. The patients were divided into three risk groups. Group I, comprised of 46 patients, had stage < or =T2a, Gleason score (GS) < or = 6, and initial PSA (iPSA) < or = 10 ng/mL. Group II comprised 188 patients with stage > or =T2b, GS > or = 7, and iPSA > or = 10, with any one factor higher. Group III included 359 patients with any two risk factors higher. The American Society for Therapeutic Radiology and Oncology definition for biochemical failure was used. RESULTS The mean follow-up was 5 years (range, 0.2-15.3). For the 611 patients, the 5-year and 10-year biochemical control (BC) rates were 77% and 73%, disease-free survival (DFS) was 67% and 49%, and cause-specific survival (CSS) was 96% and 92%, respectively. BC at 5 years for Group I patients was 96%, for Group II 88%, and for Group III patients 69%. CSS at 5 years was 100% in Group I, 99% in Group II, and 95% in Group III patients. In univariate and multiple regression analyses for BC, risk group, stage, iPSA, and GS were significant in predicting failure. However, age, follow-up interval, and ADT did not. CONCLUSIONS EBRT with HDR-BT produced excellent long-term outcomes in terms of BC, DFS, and CSS in patients with prostate cancer even for those at highest risk. Conformal HDR-BT is both a precise dose delivery system and an effective treatment for both favorable and unfavorable prostate cancer. The addition of a short course of neoadjuvant/concurrent ADT failed to improve outcome. The results were similar at all three institutions, giving credence to the reproducibility of the brachytherapy treatment.

[1]  P. Rzehak,et al.  Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[2]  A. Zietman.  The case for neoadjuvant androgen suppression before radiation therapy. , 2000, Molecular urology.

[3]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[4]  D. Cox.  Regression Models and Life-Tables , 1972 .

[5]  G. Gustafson,et al.  Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial. , 2000, International journal of radiation oncology, biology, physics.

[6]  T. Mate,et al.  High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. , 1998, International journal of radiation oncology, biology, physics.

[7]  A. Hanlon,et al.  Defining the optimal radiation dose with three‐dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques , 2001, Cancer.

[8]  T E Schultheiss,et al.  Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. , 1998, International journal of radiation oncology, biology, physics.

[9]  G. Hanks,et al.  Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[10]  D. Kuban,et al.  High-dose intensity modulated radiation therapy for prostate cancer , 2004, Current urology reports.

[11]  J. Blasko,et al.  Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. , 2002, Seminars in radiation oncology.

[12]  W. Fair,et al.  Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. , 2000, Molecular urology.

[13]  J. Letourneau,et al.  Zonal Anatomy of the Prostate , 1989 .

[14]  Michael J. Zelefsky,et al.  High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. , 2002, International journal of radiation oncology, biology, physics.

[15]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[16]  A. Zlotta,et al.  4–Year Follow–Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2–3N0M0 Prostate Cancer , 2000, European Urology.

[17]  W Cavanagh,et al.  The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  Long-term outcome following high dose rate brachytherapy and external in men with localized prostate cancer. Does elective irradiation of the pelvic lymphatic compromise the feasibility of local dose escalation? , 2000 .

[19]  D. Brenner,et al.  Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue , 2002 .

[20]  L. Sobin,et al.  TNM Atlas : Illustrated Guide to the TNM Classification of Malignant Tumours , 2005 .

[21]  T E Schultheiss,et al.  Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. , 1999, The cancer journal from Scientific American.

[22]  J Wong,et al.  Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer. , 2001, International journal of radiation oncology, biology, physics.

[23]  Chris Mitchell,et al.  Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. , 2002, International Journal of Radiation Oncology, Biology, Physics.

[24]  Rick Chappell,et al.  Is α/β for prostate tumors really low? , 2001 .

[25]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[26]  J M Collins,et al.  Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. , 1998, International journal of radiation oncology, biology, physics.

[27]  M. Gleave,et al.  Neoadjuvant hormone therapy: the Canadian trials. , 2000, Molecular urology.

[28]  E. Horwitz,et al.  Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[29]  Patrick A Kupelian,et al.  Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[30]  William R. Fair,et al.  DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER , 1998 .

[31]  J. McNeal.  The zonal anatomy of the prostate , 1981, The Prostate.

[32]  G. Gustafson,et al.  Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. , 1995, International journal of radiation oncology, biology, physics.